What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of investigation include Internal medicine, Ovarian cancer, Oncology, Surgery and Chemotherapy.
In his study, Vaccination is inextricably linked to Gastroenterology, which falls within the broad field of Internal medicine.
The various areas that Carol Aghajanian examines in his Ovarian cancer study include Combined Modality Therapy, Cancer research, Survival analysis and PARP inhibitor.
His Oncology research is multidisciplinary, incorporating elements of Survival rate, Olaparib, Retrospective cohort study and Fallopian tube.
His research in Surgery intersects with topics in Debulking, Ovary, Toxicity and Urology.
His Chemotherapy research incorporates themes from Stage and Prospective cohort study.
His most cited work include:
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (902 citations)
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (683 citations)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (554 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Surgery.
His research investigates the connection with Internal medicine and areas like Gastroenterology which intersect with concerns in Adverse effect.
His Oncology study combines topics from a wide range of disciplines, such as Stage, Paclitaxel, Endometrial cancer and Phases of clinical research.
His study in Ovarian cancer is interdisciplinary in nature, drawing from both Cancer research, Clinical trial, Olaparib, Survival rate and Fallopian tube.
His work deals with themes such as Regimen, Tolerability, Adjuvant and Urology, which intersect with Chemotherapy.
The concepts of his Surgery study are interwoven with issues in Debulking, Toxicity and Confidence interval.
He most often published in these fields:
- Internal medicine (80.25%)
- Oncology (63.27%)
- Ovarian cancer (41.61%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (80.25%)
- Oncology (63.27%)
- Ovarian cancer (41.61%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Endometrial cancer are his primary areas of study.
His Internal medicine study integrates concerns from other disciplines, such as Placebo and Rucaparib.
Carol Aghajanian has included themes like Olaparib, Newly diagnosed, Adverse effect, Veliparib and Bevacizumab in his Oncology study.
His biological study spans a wide range of topics, including Stage, Proportional hazards model and Immunotherapy.
His study looks at the intersection of Stage and topics like Cohort with Gastroenterology.
His studies in Debulking integrate themes in fields like Surgery and Ovary.
Between 2018 and 2021, his most popular works were:
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer (198 citations)
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. (150 citations)
- Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer (87 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Carol Aghajanian mainly focuses on Internal medicine, Oncology, Ovarian cancer, Endometrial cancer and Chemotherapy.
Carol Aghajanian has researched Oncology in several fields, including Clinical trial, Olaparib, Cervical cancer, Adverse effect and Bevacizumab.
His Ovarian cancer study is focused on Cancer in general.
His Endometrial cancer study combines topics in areas such as Stage, Cohort and PTEN.
Surgery covers Carol Aghajanian research in Stage.
His study looks at the intersection of Chemotherapy and topics like Adjuvant with Prospective cohort study, Urology, Brachytherapy, Depression and Myeloid.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
